Most Read Articles
3 years ago

WHO (2012) estimates that around 450 million people suffer from mental illness, with one–in–four families having at least one member with a mental illness at any point in time. According to the Malaysian Mental Health Association, mental illness is often misunderstood. For centuries, it has been seen as either possession by evil spirits, a moral weakness or punishment from a higher being. Those suffering from mental illness are commonly perceived to be restless, violent and unpredictable.

Fiel Soliven, 2 years ago
The connection between prediabetes, diabetes, and risk of hepatocellular carcinoma (HCC) in HBsAg and anti-HCV seronegative patients, as well as the association between fasting glucose and HCC were examined in this study.
10 months ago
Orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide were effective in achieving weight loss among overweight and obese adults at 52 weeks, a recent study found. Phentermine-topiramate and liraglutide were associated with the highest odds of achieving at least 5 percent weight loss.
one year ago
New drug applications approved by US FDA as of 16 - 31 Dec 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Novel drug offers hope for menopausal hot flushes

Pearl Toh
10 days ago

A novel treatment targeting the neurokinin 3 receptor (NK3R) pathway with MLE4901, a NK3R antagonist, significantly reduces the frequency and severity of menopausal hot flushes, as well as the impact on daily life of menopausal women compared with placebo, according to a study presented at The Endocrine Society Annual Meeting (ENDO 2017) in Orlando, Florida, US.

“[Treatment with MLE4901] could be practice-changing as it safely and effectively relieves hot flush symptoms without the need for oestrogen exposure,” said lead author Dr Julia Prague of Imperial College London, UK.

At baseline, the study participants reported about 13 hot flushes per day and 85 events per week. After 4 weeks of treatment, the frequency of hot flushes was significantly reduced by 45 percent to 19 events during the final week in the MLE4901 group vs 49 events in the placebo group (p<0.0001). [Lancet 2017;doi:10.1016/S0140-6736(17)30823-1]  

Objective assessment of hot flushes using a skin conductance monitor further confirmed the findings from participants’ subjective reporting, which corresponds to a 43 percent decrease (mean weekly frequency, 16.22 vs 26.91; p<0.0001).   

Hot flushes were also 41 percent less severe with MLE4901 than with placebo (mean score, 3.27 vs 5.70; p<0.0001).

In addition, women taking MLE4901 experienced 45 percent less bothersome hot flushes (mean score, 2.92 vs 5.56; p<0.0001) and 58 percent less interference from hot flushes, as rated with the Hot Flash Related Daily Interference Scale (7.94 vs 26.48; p<0.0001).

The effects of menopausal symptoms on overall life quality, scored using the Menopause-Specific Quality of Life questionnaire, improved significantly with MLE4901 in terms of vasomotor symptoms (2.05 vs 3.98; p<0.0001), physical (2.42 vs 2.93; p=0.0002), and psychosocial domains (2.18 vs 2.58; p=0.0083).

Treatment was well tolerated with no serious adverse events. By day 28 following treatment with MLE4901, three women developed elevated liver enzyme (alanine aminotransferase reached 4.5–5.9 folds the upper limit of normal) although bilirubin level was normal, and the elevation eventually normalized within 3 months.

The phase II, single-centre, crossover trial randomized 37 menopausal women with ≥7 hot flushes per day to oral MLE4901 40 mg twice daily or placebo for 4 weeks followed by a 2-week washout period before switching over to the opposite treatment.    

Due to the small number of participants and short duration of treatment, Prague acknowledged that “a larger and longer trial is needed to establish whether the treatment effect is long lasting in a greater number of individuals.”

Although the current gold standard for treating hot flushes using hormone replacement therapy is effective, it is contraindicated in some women and comes with long-term safety concerns, the researchers noted.

“NKB antagonists are an exciting development … Larger trials of clinically relevant duration examining benefits relative to established treatments are needed and might lead to a much needed addition to a very small toolbox of treatments for hot flushes,” according to Drs Jenifer Sassarini and Richard Anderson from the University of Glasgow and MRC Centre for Reproductive Health in Edinburgh, UK, respectively in a separate commentary. [Lancet 2017;doi:10.1016/S0140-6736(17)30886-3]   

 

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
3 years ago

WHO (2012) estimates that around 450 million people suffer from mental illness, with one–in–four families having at least one member with a mental illness at any point in time. According to the Malaysian Mental Health Association, mental illness is often misunderstood. For centuries, it has been seen as either possession by evil spirits, a moral weakness or punishment from a higher being. Those suffering from mental illness are commonly perceived to be restless, violent and unpredictable.

Fiel Soliven, 2 years ago
The connection between prediabetes, diabetes, and risk of hepatocellular carcinoma (HCC) in HBsAg and anti-HCV seronegative patients, as well as the association between fasting glucose and HCC were examined in this study.
10 months ago
Orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide were effective in achieving weight loss among overweight and obese adults at 52 weeks, a recent study found. Phentermine-topiramate and liraglutide were associated with the highest odds of achieving at least 5 percent weight loss.
one year ago
New drug applications approved by US FDA as of 16 - 31 Dec 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.